| Literature DB >> 32686332 |
Josephine Kermer1, Julius Traber1, Wolfgang Utz1, Pierre Hennig1, Marius Menza2, Bernd Jung3, Andreas Greiser4, Philipp Barckow5, Florian von Knobelsdorff-Brenkenhoff1,6, Agnieszka Töpper1,7, Edyta Blaszczyk1,8, Jeanette Schulz-Menger1,8,9.
Abstract
AIMS: Heart failure with preserved ejection fraction is still a diagnostic and therapeutic challenge, and accurate non-invasive diagnosis of left ventricular (LV) diastolic dysfunction (DD) remains difficult. The current study aimed at identifying the most informative cardiovascular magnetic resonance (CMR) parameters for the assessment of LVDD. METHODS ANDEntities:
Keywords: Cardiovascular magnetic resonance; Diastolic dysfunction; Heart failure with preserved ejection fraction; Left atrium; Myocardial deformation; Tissue tracking
Mesh:
Year: 2020 PMID: 32686332 PMCID: PMC7524101 DOI: 10.1002/ehf2.12846
Source DB: PubMed Journal: ESC Heart Fail ISSN: 2055-5822
Figure 1(A) Study group definition and number of patients. (B) Study protocol. LVEDP, left ventricular end‐diastolic pressure; NT‐proBNP, N‐terminal pro‐brain natriuretic peptide.
Figure 2Overview cardiovascular magnetic resonance techniques. Left ventricular–midventricular short‐axis view of myocardial deformation via tagging in (A1) end‐diastole and (A2) end‐systole. Left ventricular–midventricular short‐axis view of colour‐encoded myocardial velocity tissue phase mapping in (B1) end‐diastole and (B2) end‐systole. Assessment of cardiovascular magnetic resonance tissue tracking: (C1) end‐diastolic contouring and tissue tracking and (C2) end‐systolic myocardial deformation. (C3) Radial strain and (C4) strain rate: the graphs show phases of one cardiac cycle. The definitions were as follows: end‐systole = phase of aortic valve closure; isovolumetric relaxation time (IVRT) = time between end‐systole and mitral valve opening; and end‐diastole = phase of mitral valve closure. Peaks of myocardial strain rate were defined as follows: (i) preE = peak within IVRT; (ii) E = peak between mitral valve opening and start of diastolic plateau phase; and (iii) A = peak between end of diastolic plateau phase and end‐diastole. (D) Stack of short‐axis views of left atrial (LA) and contouring in LA diastolic phase. (E) Measurement of LA plane and diameters in long‐axis two‐chamber, three‐chamber, and four‐chamber views. (F) Assessment of phase contract transmitral flow velocities: basal short‐axis views with and without colour‐encoded visualization and contouring of the mitral annulus; transmitral flow velocity curve with early (E) and late (A) diastolic peak velocities.
Characteristics of the study population
| Study groups | |||
|---|---|---|---|
| Without diastolic dysfunction (DD−) | Uncertain diastolic function (DD±) | With diastolic dysfunction (DD+) | |
| Sample size ( | 26 | 9 | 15 |
| Sex (male|female) | 16|10 | 9|0 | 9|6 |
| Age (years) | 66.6 ± 8.9 | 68.0 ± 7.3 | 70.5 ± 7.4 |
| BMI (kg/m2) | 26.7 ± 3.0 | 28.6 ± 4.7 | 29.7 ± 3.2 |
| 6MWD (m) | 509 ± 76 | 487 ± 114 | 446 ± 122 |
| LVEDP (mmHg) | 8 ± 3 | 14 ± 1 | 20 ± 5 |
| E/E′ | 8.5 ± 2.0 | 10.8 ± 1.4 | 10.1 ± 2.0 |
| NT‐proBNP (ng/mL) | 184 ± 151 | 157 ± 107 | 447 ± 422 |
| Heart rate (b.p.m.) | 68 ± 11 | 70 ± 11 | 64 ± 8 |
| Arterial hypertension (%) | 84.6 | 100.0 | 93.3 |
| Coronary artery disease (%) | 88.5 | 100.0 | 80.0 |
| One‐vessel disease (%) | 23.1 | 33.3 | 26.7 |
| Two‐vessel disease (%) | 34.6 | 55.6 | 20.0 |
| Three‐vessel disease (%) | 30.8 | 11.1 | 33.3 |
| Diabetes mellitus (%) | 34.6 | 11.1 | 33.3 |
| Hyperlipoproteinaemia (%) | 38.5 | 66.7 | 60.0 |
6MWD, 6 min walking distance; BMI, body mass index; E/E′, ratio of early transmitral flow velocity (E) and early diastolic lengthening velocity (E′); LVEDP, left ventricular end‐diastolic pressure; NT‐proBNP, N‐terminal pro‐brain natriuretic peptide.
Data are shown as mean ± standard deviation.
For P < 0.05 compared with DD−.
For P < 0.05 compared with DD±.
Figure 3Diagnostic performance of measurements of the left atrium and walking distance to identify diastolic dysfunction. (A) Receiver operating characteristic curves of left atrial (LA) end‐diastolic volume (EDV), area of three‐chamber view, and triplane mean area indexed to height (H). (B) Receiver operating characteristic curve of walking distance assessed by 6 min walk test.
Findings of LV and LA analysis of DD− and DD+
| DD− | DD+ |
| ||
|---|---|---|---|---|
| Left ventricle | ||||
| LVEDV (mL) | 122.6 ± 34.3 | 130.5 ± 32.4 | 0.429 | |
| LVEDV/BSA (mL/m2) | 63.7 ± 14.0 | 66.3 ± 14.9 | 0.639 | |
| LV‐SV (mL) | 83.3 ± 21.3 | 86.0 ± 22.2 | 0.548 | |
| LVEF (%) | 69.0 ± 7.6 | 66.0 ± 7.4 | 0.334 | |
| LVM (g) | 96.5 ± 29.9 | 110.2 ± 30.6 | 0.092 | |
| LVM/H (g/cm) | 0.6 ± 0.1 | 0.7 ± 0.2 | 0.050 | |
| LVM/BSA (g/m2) | 49.9 ± 11.3 | 55.6 ± 12.3 | 0.079 | |
| LVRI (g/mL) | 0.8 ± 0.1 | 0.9 ± 0.2 | 0.412 | |
| Left atrium—quantification based on full coverage (volume) | ||||
| LA‐EDV (mL) | 74.4 ± 17.2 | 93.3 ± 26.2 | 0.014 | |
| LA‐EDV/H (mL/cm) | 0.4 ± 0.1 | 0.6 ± 0.1 | 0.010 | |
| LA‐EDV/BSA (mL/m2) | 39.2 ± 8.9 | 46.6 ± 12.0 | 0.069 | |
| LA‐SV (mL) | 38.7 ± 8.4 | 41.2 ± 13.0 | 0.578 | |
| LAEF (%) | 52.7 ± 7.4 | 45.7 ± 13.1 | 0.151 | |
| Left atrium—quantification based on area | ||||
| LA area 4CV (mm2) | 20.1 ± 6.2 | 22.1 ± 5.4 | 0.169 | |
| LA area 4CV/H (mm2/cm) | 0.12 ± 0.03 | 0.13 ± 0.03 | 0.188 | |
| LA area 3CV (mm2) | 18.6 ± 3.8 | 22.3 ± 5.9 | 0.033 | |
| LA area 3CV/H (mm2/cm) | 0.11 ± 0.02 | 0.13 ± 0.03 | 0.026 | |
| LA area 2CV (mm2) | 20.4 ± 5.5 | 24.8 ± 5.6 | 0.035 | |
| LA area 2CV/H (mm2/cm) | 0.12 ± 0.03 | 0.15 ± 0.03 | 0.061 | |
| LA area mean biplane (mm2) | 20.2 ± 5.5 | 23.5 ± 4,8 | 0.084 | |
| LA area mean biplane/H (m2/cm) | 0.12 ± 0.03 | 0.14 ± 0.03 | 0.079 | |
| LA area mean triplane (mm2) | 19.7 ± 4.6 | 23.1 ± 5.1 | 0.084 | |
| LA area mean triplane/H (m2/cm) | 0.12 ± 0.03 | 0.13 ± 0.03 | 0.046 | |
2/3/4CV, two‐chamber/three‐chamber/four‐chamber view; BSA, body surface area; DD−, patients without diastolic dysfunction; DD+, patients with diastolic dysfunction; EDV, end‐diastolic volume; H, body height; LA, left atrial; LAEF, left atrial ejection fraction; LV, left ventricular; LVEF, left ventricular ejection fraction; LVM, left ventricular mass; LVRI, left ventricular remodelling index; SV, stroke volume.
Data are shown as mean ± standard deviation.
For P < 0.05.
Figure 4Regional myocardial differences between patients with and without diastolic dysfunction. Significant differences are highlighted in red. (A) Tissue tracking: early (E) and atrial (A) diastolic peaks of circumferential and radial strain rate ± standard deviation. P‐values of segments showing significant differences are Ecc A peak: basal inferolateral (P = 0.007) and apical anterior (P = 0.014); Err E peak: basal inferolateral (P = 0.030); and Err A peak: basal inferolateral (P = 0.033) and apical anterior (P = 0.019). (B) Tissue phase mapping (TPM) radial and longitudinal peak diastolic velocities ± standard deviation. P‐values of segments showing significant differences are Vr basal inferolateral (P = 0.018), Vz basal anterolateral (P = 0.007), and Vz medial anterior (P = 0.044). (C) Tagging [spatial modulation of magnetization (SPAMM) and complementary spatial modulation of magnetization (CSPAMM)]: diastolic peak of circumferential strain rate ± standard deviation.